Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04716-9
This work developed and validated a computational pathology biomarker—the TROP2 normalized membrane ratio—that quantifies subcellular TROP2 localization and predicts improved progression-free and overall survival with datopotamab deruxtecan in patients with nonsquamous non-small-cell lung cancer lacking actionable genomic alterations.
